Financials data is unavailable for this security.
View more
Year on year Hangzhou Alltest Biotech Co Ltd 's revenues fell -77.73% from 3.39bn to 754.70m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 1.18bn to 180.58m, a -84.75% decrease.
| Gross margin | 53.69% |
|---|---|
| Net profit margin | 34.03% |
| Operating margin | 38.05% |
| Return on assets | 6.74% |
|---|---|
| Return on equity | 7.25% |
| Return on investment | 7.22% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Hangzhou Alltest Biotech Co Ltd fell by 665.22m. However, the company earned 24.76m from its operations for a Cash Flow Margin of 3.28%. In addition the company used 140.67m on investing activities and also paid 558.79m in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 50.02 |
|---|---|
| Tangible book value per share | 48.62 |
More ▼
Balance sheet in CNYView more
| Current ratio | 11.02 |
|---|---|
| Quick ratio | 10.46 |
| Total debt/total equity | 0.0022 |
|---|---|
| Total debt/total capital | 0.0022 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -77.80% and -84.64%, respectively. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
| Div yield(5 year avg) | -- |
|---|---|
| Div growth rate (5 year) | -- |
| Payout ratio (TTM) | 42.05% |
| EPS growth(5 years) | 18.73 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 478.33 |
More ▼
